You are here: Home » Current Affairs » Coronavirus » News
Business Standard

EU drug agency clears coronavirus therapeutics Ronapreve, Regkiron

EMA will now send its recommendations for both medicines to the European Commission for a rapid legally binding decision.

Topics
Coronavirus | Coronavirus Vaccine | corona

ANI 

Coronavirus vaccine
Coronavirus vaccine

The European Medicines Agency recommended on Thursday authorizing two antibody medicines, Ronapreve and Regkirona, for COVID-19 treatment in patients who are at risk of their disease becoming severe.

The agency's human medicines committee said the drugs were based on monoclonal antibodies, designed to block the binding of the virus's spike protein in the early stages of infection. Their use in patients who did not need ventilation reduced the number of hospitalizations.

"Ronapreve and Regkirona are the first monoclonal antibody medicines to receive a positive opinion from the CHMP for COVID-19," the agency said in a statement.

EMA will now send its recommendations for both medicines to the European Commission for a rapid legally binding decision.

Health Commissioner Stella Kyriakides said the two medicines were from a shortlist of five treatments the EU hoped to authorize for use by the end of the year. Member states can already call upon the Commission's contract for 55,000 Ronapreve doses.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Fri, November 12 2021. 07:54 IST
RECOMMENDED FOR YOU